Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”) today announced the appointment of Rachelle Jacques
to its Board of Directors.
Ms. Jacques has more than two decades of
experience in U.S. and global commercial leadership and marketing,
including launching multiple medicines for rare diseases. She
currently serves as Chief Executive Officer of Enzyvant
Therapeutics, Inc, a private biopharmaceutical company focused on
developing therapies for patients with rare diseases. Prior to
joining Enzyvant, Ms. Jacques was the Senior Vice President and
Global Complement Franchise Head at Alexion Pharmaceuticals, Inc.,
responsible for global commercialization strategy and execution of
therapies for rare diseases. Previously, she was Vice President of
U.S Hematology Marketing at Shire plc, which acquired Baxalta Inc.
She also served as Vice President of Business Operations at Baxalta
after its spinoff from Baxter International Inc.
“We are delighted to welcome Rachelle to our
Board of Directors,” said Alan Holmer, Chairman of Corbus’ Board of
Directors. “She brings invaluable biopharmaceutical industry
perspective to Corbus gained from her over 25-year career. We look
forward to benefiting from her exceptional insights into business
operations as well as global and country-specific commercial
marketing and sales as the Company lays the groundwork for its
commercialization strategy.”
“I have come to recognize and admire the
pioneering work Corbus is undertaking in the development of
treatments for rare inflammatory and fibrotic diseases, and I am
excited to join a team that shares my dedication to patient-centric
health solutions,” stated Ms. Jacques. “I look forward to working
with Corbus’ leadership team and my fellow directors as the Company
develops its go-to-market commercial strategies ahead of topline
results from several key studies in 2020.”
“Rachelle is an accomplished biopharmaceutical
executive with extensive commercial experience building and scaling
successful drug franchises, and I am pleased to welcome her to our
Board,” added Yuval Cohen, Ph.D., Chief Executive Officer of
Corbus. “She will be a real asset to our team as we bring our
much-needed therapies to market and continue to advance our vision
to become the leader in the treatment of inflammatory and fibrotic
diseases by targeting the endocannabinoid system.”
With Ms. Jacques’ appointment, Corbus’ Board has
been expanded and is now composed of seven highly qualified
directors, five of whom are independent.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its pipeline of endocannabinoid
system-targeting synthetic drug candidates. The Company's lead
product candidate, lenabasum, is a novel, synthetic, oral,
selective cannabinoid receptor type 2 (CB2) agonist designed to
resolve chronic inflammation and fibrotic processes. Lenabasum is
currently being evaluated in systemic sclerosis, cystic fibrosis,
dermatomyositis, and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug
candidates from more than 600 novel compounds targeting the
endocannabinoid system. The pipeline includes CRB-4001, a 2nd
generation, peripherally-restricted, selective cannabinoid receptor
type 1 (CB1) inverse agonist. Potential indications for CRB-4001
include NASH, among others. Corbus plans to start a Phase 1 study
of CRB-4001 in 2019, intended to be followed by a National
Institutes of Health (NIH)-funded proof-of-concept Phase 2
study.
For more information, please
visit www.CorbusPharma.com and connect with the Company on
Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Institutional Investor InquiriesTed Jenkins,
Senior Director, Investor Relations and CommunicationsPhone: +1
(617) 415-7745Email: ir@corbuspharma.com
All Other Investor InquiriesJenene ThomasJenene
Thomas Communications, LLCPhone: +1 (833) 475-8247Email:
crbp@jtcir.com
Media InquiriesLindsey Smith, Associate
Director, Investor Relations and Corporate CommunicationsPhone: +1
(617) 415-7749Email: mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jul 2023 to Jul 2024